Insulin syringes 30g 3 10 cc

In vivo imaging studies were performed on NOD/SCID nude mice (male, 8–10 weeks old). All experimental protocols involving live animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC No. 2021031802) of Chang Gung Memorial Hospital and were performed in accordance with the Animal Protection Regulations of the Council of Agriculture, Executive Yuan (R.O.C.) and the guidelines of National Research Council (USA) for the care and use of laboratory animals. For lung tumor implantation, mice were anesthetized using an intraperitoneal injection of Zoletil^® (Virbac, France) and placed in a face-up position. A solution of 10 µL RPMI-1640 medium (5 × 10⁴ CL1-5-Luc/GFP cells) and 10 µL Basement Membrane Matrix (BD, USA) was directly injected (3 mm depth) into the right lung of the mice via BD Insulin Syringes 30G 3/10 cc (BD, USA).

NOD-SCID mice (6–8 weeks, female) were anesthetized using an intraperitoneal injection of Zoletil 100 (Virbac) and put in a face-up position. Then, 2 × 10⁶ HepG2-Red-Fluc cells in a solution containing 10 μL of PBS and 10 μL of Basement Membrane Matrix (BD) were surgically implanted into either right or left lobe of the liver using BD Insulin Syringes 30 G 3/10cc (BD). The wound was sutured using CT204 Chromic Catgut (20 mm, 75 cm, UNIK SURGICAL SUTURES MFG. CO.) as well as NC193 Monofilament Nylon (19 mm, 45 cm, UNIK SURGICAL SUTURES MFG. CO.) and the mice were allowed to rest until they fully recover. The tumor growth of HepG2-Red-FLuc hepatocellular carcinoma cells were monitored by the IVIS imaging system (Caliper Life Sciences). The maximal tumor burden permitted by Institutional Animal Care and Use Committee of NCKU was the weight of tumor should not exceed 10% of body weight and without ascites formation. All the experimental mice with orthotopic hepatocellular carcinoma were sacrifice before reaching the above standard.